Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Akero Therapeutics Inc.

    NASDAQ: AKRO · Real-Time Price · USD
    56.30
    1.27 (2.30%)
    At close: Jun 26, 2025, 3:59 PM
    56.28
    -0.04%
    Pre-market: Jun 27, 2025, 04:01 AM EDT

    Akero Therapeutics Statistics

    Share Statistics

    Akero Therapeutics has 79.72M shares outstanding. The number of shares has increased by 15.14% in one year.

    Shares Outstanding

    n/a
    		 79.72M

    Shares Change (YoY)

    n/a
    		 15.14%

    Shares Change (QoQ)

    n/a
    		 14.07%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 71.74M

    Failed to Deliver (FTD) Shares

    n/a
    		 2,918

    FTD / Avg. Volume

    n/a
    		 0.18%

    Short Selling Information

    The latest short interest is 6.91M, so 8.67% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 6.91M

    Short % of Shares Out

    n/a
    		 8.67%

    Short % of Float

    n/a
    		 8.92%

    Short Ratio (days to cover)

    n/a
    		 2.76

    Valuation Ratios

    The PE ratio is -7.41 and the forward PE ratio is -12.63. Akero Therapeutics's PEG ratio is -0.25.

    PE Ratio

    n/a
    		 -7.41

    Forward PE

    n/a
    		 -12.63

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 28.6

    PB Ratio

    n/a
    		 2.49

    P/FCF Ratio

    n/a
    		 -8.12

    PEG Ratio

    n/a
    		 -0.25
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Akero Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 19.38, with a Debt / Equity ratio of 0.05.

    Current Ratio

    n/a
    		 19.38

    Quick Ratio

    n/a
    		 19.38

    Debt / Equity

    n/a
    		 0.05

    Debt / EBITDA

    n/a
    		 -0.13

    Debt / FCF

    n/a
    		 -0.16

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-3,653,043.48

    Employee Count

    n/a
    		 69

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 140.6% in the last 52 weeks. The beta is -0.16, so Akero Therapeutics's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.16

    52-Week Price Change

    n/a
    		 140.6%

    50-Day Moving Average

    n/a
    		 46.7

    200-Day Moving Average

    n/a
    		 38.14

    Relative Strength Index (RSI)

    n/a
    		 68.01

    Average Volume (20 Days)

    n/a
    		 1,610,676

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -285.42M

    Net Income

    n/a
    		 -252.06M

    EBITDA

    n/a
    		 -285.42M

    EBIT

    n/a
    		 -256.73M

    Earnings Per Share (EPS)

    n/a
    		 -3.75
    Full Income Statement

    Balance Sheet

    The company has 340.24M in cash and 36.46M in debt, giving a net cash position of 303.78M.

    Cash & Cash Equivalents

    n/a
    		 340.24M

    Total Debt

    n/a
    		 36.46M

    Net Cash

    n/a
    		 303.78M

    Retained Earnings

    n/a
    		 -826.16M

    Total Assets

    n/a
    		 1.16B

    Working Capital

    n/a
    		 670.71M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -230.11M and capital expenditures 0, giving a free cash flow of -230.11M.

    Operating Cash Flow

    n/a
    		 -230.11M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -230.11M

    FCF Per Share

    n/a
    		 -3.43
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    AKRO does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for AKRO is $76.5, which is 35.9% higher than the current price. The consensus rating is "Strong Buy".

    Price Target

    n/a
    		 $76.5

    Price Target Difference

    n/a
    		 35.9%

    Analyst Consensus

    n/a
    		 Strong Buy

    Analyst Count

    n/a
    		 6
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 28.93

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist